Sodium-electric and semi-solid, half flame and half seawater | Jianzhi Research

Thanks to the new energy autos achieving a record high in delivery, the production, sales and installation volume of power batteries also hit a new high in June this year in all dimensions.

wallstreetcnJul 11 06:18 ET

In 2019, the head brokerage's secretary was appointed as the "older insurance agent".

China Securities Co., Ltd., a leading brokerage firm, recently announced an important personnel change. The company's board of directors has approved the appointment of Liu Naisheng as the company's board secretary, and Wang Guangxue will no longer hold this position. Liu Naisheng is a veteran investment banker and the first generation of securities salespeople in China. He has led successful underwriting projects for numerous companies and is best known for overseeing the IPO projects for Contemporary Amperex Technology and the representative Beijing-Shanghai High Speed Railway. As a seasoned securities industry veteran, Liu Naisheng's appointment as board secretary after seven years of serving as a senior executive (executive committee member) at China Securities Co., Ltd. is certainly worth following in terms of his future contributions. According to publicly available information about skilled post-70s workers, Liu Naisheng belongs to the post-70s generation of securities professionals.

wallstreetcnJul 10 10:21 ET

AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.

Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.

wallstreetcnJul 1 22:02 ET

Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET

"Top real estate player in Fujian province" becomes third place in Hangzhou.

Author: Cao Anxun Editor: Zhou Zhiyu After becoming the top newcomer among Fujian property companies, JF ups the pace of expansion. On June 14th, China Resources Land spent CNY 5.76 billion to purchase the land of Wuyuan Bay, Xiamen. According to CRIC, from January to May, JF's new land value totaled CNY 43.54 billion, ranking third in the country behind China Resources Land and China State Construction's One Product, and had landed in Longyan, Hangzhou, Wuhan, Changsha and other places. Particularly in Hangzhou, according to 36 Krypton, JF acquired approximately 220,000 square meters of project GFA with a premium of less than 30% since the beginning of the year.

wallstreetcnJun 18 11:42 ET

Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin

On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.

wallstreetcnMay 29 09:12 ET